Hostname: page-component-78c5997874-g7gxr Total loading time: 0 Render date: 2024-11-11T07:15:35.054Z Has data issue: false hasContentIssue false
  • English
  • Français

Sustained drug delivery optimizes long-term treatment of patients with schizophrenia

Published online by Cambridge University Press:  24 June 2014

Pierre S. Chue ,
Peter D'Hoore  and
J. Michael Ramstack
Pierre S. Chue*
Affiliation:
Department of Psychiatry, University of Alberta Hospital, Alberta, Canada
Peter D'Hoore
Affiliation:
Johnson & Johnson Pharmaceutical Research and Development, Beerse, Belgium
J. Michael Ramstack
Affiliation:
Alkermes, Inc, Cambridge, MA, USA
*
Dr Pierre Chue, 3rd Floor, 9942-108 Street, Edmonton, Alberta, Canada. Tel: +1 780 428 1776; Fax: +1 780 425 9317; E-mail: pchue@ualberta.ca
Get access Rights & Permissions [Opens in a new window]

Abstract

Chronic disorders such as schizophrenia require long-term treatment programs in order to maintain patients at the lowest level of symptomatology, reduce the likelihood of psychotic relapse, and support achievement of remission and recovery. Evidence suggests that treatment with long-acting injectable antipsychotics reduces the impact of partial compliance and provides predictable release of medication, assuring continuous therapeutic coverage. Until recently, only conventional antipsychotic agents were available in long-acting formulations, thereby foregoing the advantages of the atypical class. Atypical agents which are given orally have been shown to provide long-term efficacy and tolerability benefits compared with conventional agents, but are limited by the need for daily administration. The most recent pharmacological strategy to achieve optimal maintenance treatment has been to combine the benefits of an atypical antipsychotic with delivery in a water-based long-acting formulation. The first antipsychotic to achieve this combination – long-acting risperidone – may thus represent an important advance in the optimization of long-term treatment outcomes in patients with schizophrenia.

Keywords

antipsychoticcompliancelong actingmaintenancetolerability
Type
Original Article
Information
Acta Neuropsychiatrica , Volume 16 , Issue 6 , December 2004 , pp. 319 - 325
Copyright
Copyright © 2004 Blackwell Munksgaard

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Kane, JM, Aguglia, E, Altamura, ACet al. Guidelines for depot antipsychotic treatment in schizophrenia. Eur Neuropsychopharmacol 1998;8: 55–66. CrossRefGoogle Scholar
Liberman, R, Kopelowicz, A.Recovery from schizophrenia: a challenge for the 21st century. Int Rev Psychiatry 2002;14: 245–255. CrossRefGoogle Scholar
Liberman, R, Wallace, C, Blackwell, G, Eckman, T, Vaccaro, J, Kuehnel, T.Innovations in skills training for the seriously mentally ill: the UCLA Social & Independent Living Skills modules. Innovat Res 1993;2: 43–60. Google Scholar
Johnson, D.Depot neuroleptics. In: Barnes, T (ed). Antipsychotic drugs and their side-effects. London: Academic Press, 1993: 205–212. Google ScholarPubMed
Robinson, D, Woerner, MG, Alvir, JMet al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999;56: 241–247. CrossRefGoogle ScholarPubMed
Johnson, DA, Pasterski, G, Ludlow, JM, Street, K, Taylor, RD.The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences. Acta Psychiatr Scand 1983;67: 339–352. CrossRefGoogle ScholarPubMed
Kane, JM.Schizophrenia. N Eng J Med 1996;334: 34–41. CrossRefGoogle ScholarPubMed
Kissling, W.The current unsatisfactory state of relapse prevention in schizophrenic psychoses – suggestions for improvement. Clin Neuropharmacol 1991;14(Suppl. 2): S33–S44. Google Scholar
Ayuso-Gutierrez, JL, Del Rio Vega, JM.Factors influencing relapse in the long-term course of schizophrenia. Schizophr Res 1997;28: 199–206. CrossRefGoogle ScholarPubMed
American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. Am J Psychiatry 1997;154(Suppl. 4):1–63. CrossRefGoogle ScholarPubMed
McEvoy, J, Scheifler, P, Frances, A.Expert consensus guideline series. Treatment of schizophrenia. J Clin Psychiatry 1999;60(Suppl. 11):1–80. Google Scholar
Misdrahi, D, Llorca, PM, Lancon, C, Bayle, FJ.Compliance in schizophrenia: predictive factors, therapeutical considerations and research implications. Encephale 2002;28(3 Part 1):266–272. Google ScholarPubMed
Buchanan, A.A two-year prospective study of treatment compliance in patients with schizophrenia. Psychol Med 1992;22: 787–797. CrossRefGoogle ScholarPubMed
Fleischhacker, WW, Meise, U, Guenther, V, Kurz, M.Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatr Scand Suppl 1994;89(Suppl. 382):11–15. Google Scholar
Weiden, P, Aquila, R, Standard, J.Atypical antipsychotic drugs and long-term outcome in schizophrenia. J Clin Psychiatry 1996;57(Suppl. 11):53–60. Google Scholar
Davis, JM, Matalon, L, Watanabe, MD, Blake, L, Metalon, L.Depot antipsychotic drugs. Place in therapy. Drugs 1994;47: 741–773. CrossRefGoogle ScholarPubMed
Perkins, DO.Adherence to antipsychotic medications. J Clin Psychiatry 1999;60(Suppl. 21):25–30. Google ScholarPubMed
Kane, JM.Problems of compliance in the outpatient treatment of schizophrenia. J Clin Psychiatry 1983;44: 3–6. Google ScholarPubMed
Docherty, JP, Kozma, C, Grogg, A, Lasser, R. Antipsychotic maintenance in schizophrenia: partial compliance and clinical outcome. American College of Neuropsychopharmacology scientific abstracts, American College of Neuropsychopharmacology 41st Annual Meeting, December 8–12, 2002, San Juan, Puerto Rico:179, Abstract 154.Google Scholar
Valenstein, M, Copeland, LA, Blow, FCet al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care 2002;40: 630–639. CrossRefGoogle ScholarPubMed
Kozma, C, Grogg, A. Medication compliance and hospitlaization in schizophrenia. Presented at the 6th meeting of the College of Psychiatric and Neurologic Pharmacists, 1–4 May, 2003 Poster Abstracts pp10.Google Scholar
Love, R.Strategies for increasing treatment compliance: the role of long-acting antipsychotics. Am J Health Syst Pharm 2002;59(Suppl. 8):S10–S15. Google ScholarPubMed
Gerlach, J.Oral versus depot administration of neuroleptics in relapse prevention. Acta Psychiatr Scand Suppl 1994;382: S28–S32. CrossRefGoogle ScholarPubMed
Young, JL, Zonana, HV, Shepler, L.Medication noncompliance in schizophrenia: codification and update. Bull Am Acad Psychiatry Law 1986;14: 105–122. Google ScholarPubMed
Cramer, JA, Rosenheck, R.Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 1998;49: 196–201. CrossRefGoogle ScholarPubMed
Greenberg, RN.Overview of patient compliance with medication dosing: a literature review. Clin Ther 1984;6: 592–599. Google ScholarPubMed
Haldol. Summary of Product Characteristics, 2001.Google Scholar
Fluphenazine. British Notary Fomulary; accessed May 2003.Google Scholar
Remington, GJ, Adams, ME.Depot neuroleptic therapy: clinical considerations. Can J Psychiatry 1995;40(3Suppl. 1):S5–S11. Google ScholarPubMed
Jacobsson, L, Odling, H.Psykologiska aspekter po depabehandling vid schizofrena syndrom. Lakartidningen 1980;77: 3522–3526. Google Scholar
Walburn, J, Gray, R, Gournay, K, Quraishi, S, David, AS.Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry 2001;179: 300–307. CrossRefGoogle ScholarPubMed
Wistedt, B.How does the psychiatric patient feel about depot treatment, compulsion or help. Nord J Psychiatry 1995;49(Suppl. 35):41–46. CrossRefGoogle Scholar
Bloch, Y, Mendlovic, S, Strupinsky, S, Altshuler, A, Fennig, S, Ratzoni, G.Injections of depot antipsychotic medications in patients suffering from schizophrenia: do they hurt? J Clin Psychiatry 2001;62: 855–859. CrossRefGoogle ScholarPubMed
Hamann, GL, Egan, TM, Wells, BG, Grimmig, JE.Injection site reactions after intramuscular administration of haloperidol decanoate 100 mg/mL. J Clin Psychiatry 1990;51: 502–504. Google ScholarPubMed
Buchanan, R.Clozapine: efficacy and safety. Schizophr Bull 1995;21: 579–591. CrossRefGoogle ScholarPubMed
Tollefson, GD, Beasley, CM Jr, Tran, PVet al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154: 457–465. Google ScholarPubMed
Kennedy, E, Song, F, Hunter, R, Clarke, A, Gilbody, S.Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database Syst Rev 2000;(2):CD000440. Google Scholar
Voruganti, L, Cortese, L, Oyewumi, L, Cernovsky, Z, Zirul, S, Awad, A.Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizo Res 2000;43: 135–145. CrossRefGoogle ScholarPubMed
Wahlbeck, K, Cheine, M, Essali, MA.Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev 2000; 2: CD000059. Google Scholar
Csernansky, JG, Mahmoud, R, Brenner, R.A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Eng J Med 2002;346: 16–22. CrossRefGoogle ScholarPubMed
Davis, J, Chen, N.Clinical profile of an atypical antipsychotic: risperidone. Schizophr Bull 2002;28: 43–61. CrossRefGoogle ScholarPubMed
Csernansky, JG, Schuchart, EK.Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics. CNS Drugs 2002;16: 473–484. CrossRefGoogle ScholarPubMed
Glick, I, Davis, JNC.A meta-analysis of the efficacy of second-generation antipsychotics. Schizophr Res 2003;60(1 Suppl):285. CrossRefGoogle Scholar
Srisurapanont, M, Disayavanish, C, Taimkaew, K.Quetiapine for schizophrenia. Cochrane Database Syst Rev 2000;3: CD000967. Google Scholar
Hirsch, SR, Kissling, W, Bauml, J, Power, A, O'Connor, R.A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. J Clin Psychiatry 2002;63: 516–523. CrossRefGoogle ScholarPubMed
Hamilton, SH, Edgell, ET, Revicki, DA, Breier, A.Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample. Int Clin Psychopharmacol 2000;15: 245–255. CrossRefGoogle Scholar
Lewis, D.Controlled release of bioactive agents from lactide/glycolide polymers. In: Chasin, M, Langer, R, eds. Biodegradable polymers as drug delivery systems. New York: Marcel Dekker, 1990: 1–41. Google Scholar
Kane, JM, Eerdekens, M, Lindenmayer, JP, Keith, S, Lesem, M, Karcher, K.Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotics. Am J Psychiatry 2003;160: 1125–1132. CrossRefGoogle Scholar
Eerdekens, M, Rasmussen, A, Vermeulen, A, Lowenthal Peer, V.Kinetics and safety of a novel long-acting risperidone formulation. Int J Neuropsychopharmacol 2000;3(Suppl. 1):135. Google Scholar
Fleischhacker, WW, Eerdekens, M, Karcher, Ket al. Treatment of schizophrenia with long-acting injectable risperidone: a 12 month evaluation of the first long-acting 2nd generation antipsychotic. J Clin Psychiatry 2003;64: 1250–1257. CrossRefGoogle Scholar
Gharabawi, G, Lasser, R, Bossie, C, Zhu, Y, Baldessarini, R. Enhanced one-year outcomes with three doses of long-acting injectable risperidone in 336 chronically psychotic, stable patients switched from oral risperidone. Presented as a poster at the American College of Neuropsychopharmacology 41st Annual Meeting, December 8–12, 2002, San Juan, Puerto Rico. Poster No 175.Google Scholar
Lasser, R, Bossie, C, Gharabawi, G, Turner, M.Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone. Eur Psychiatry 2004;19: 219–225.CrossRefGoogle ScholarPubMed
van Os, J, Bossie, C, Lasser, R.Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone. Int Clin Psychopharmacol 2004;19: 229–232. Google ScholarPubMed
Nasrallah, H, Duchesne, I, Mehnert, A, Janagap, C. Long-acting risperidone injection improves quality of life. American College of Neuropsychopharmacology scientific abstracts, American College of Neuropsychopharmacology 41st Annual Meeting, December 8–12, 2002, San Juan, Puerto Rico.Google Scholar
Freyberger, HJ, Eerdekens, M, Duchesne, I, Mehnert, A, Rabinowitz, J.Patient satisfaction with their medication during long-term treatment with long-acting risperidone injection. Int J Neuropsychopharmacol 2002;5(Suppl. 1):S189. Google Scholar
Remington, G, Devos, E, Eerdekens, M, Duchesne, I, Leal, A, Mehnert, A.Treatment with long-acting risperidone injection reduces healthcare resource use. Int J Neuropsychopharmacol 2002;5(Suppl. 1):S189. Google Scholar